FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab
Treatment options for relapsed/refractory multiple myeloma continue to expand with FDA’s accelerated approval of teclistamab (Tecvayli). The approval stipulates use of the bispecific antibody in adults who have received at least four prior therapies, including an immunomodulator, a proteasome inhibitor, and an anti-CD38 antibody (triple-class refractory disease). The first approved drug of its kind, teclistamab […]
Early Promise for Pembrolizumab Plus Chemo in RR Hodgkin’s Lymphoma
A chemoimmunotherapy regimen led to a 100% response rate as second-line therapy for relapsed/refractory (RR) classical Hodgkin lymphoma (cHL), a small phase II trial showed. All 38 evaluable patients achieved objective responses with the combination of pembrolizumab (Keytruda), gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD), including complete responses in 36 of 38 cases. All but two […]